Elicio Therapeutics (ELTX) Assets Average (2021 - 2026)
Elicio Therapeutics' (ELTX) quarterly Assets Average came in at $24.3 million in Q1 2026, down 13.85% YoY from $28.2 million in Q1 2025, and down 10.33% on a QoQ basis from $27.1 million in Q4 2025.
Elicio Therapeutics (ELTX) Assets Average (2021 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 6 years of Assets Average data on file, last reported at $24.3 million in Q1 2026.
- Quarterly Assets Average fell 13.85% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (down 13.85% YoY) and the FY2025 annual result came in at $27.0 million, down 2.32% from the prior year.
- Assets Average eased to $24.3 million in Q1 2026, from $27.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $88.9 million in Q1 2022 to a low of $20.1 million in Q2 2024.
- A 5-year average of $38.3 million and a median of $29.1 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average tumbled 63.76% — and 2025, when it surged 43.44%.
- Tracing ELTX's Assets Average over 5 years: stood at $42.0 million in 2022, then slumped by 30.78% to $29.1 million in 2023, then gained by 14.51% to $33.3 million in 2024, then retreated by 18.66% to $27.1 million in 2025, then dropped by 10.33% to $24.3 million in 2026.
- The last three Assets Average figures came in at $24.3 million (Q1 2026), $27.1 million (Q4 2025), and $28.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | 27.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.01 Mn |
| Mar 31, 2026 | 24.28 Mn |
| Dec 31, 2025 | 27.07 Mn |
| Sep 30, 2025 | 28.91 Mn |
| Jun 30, 2025 | 28.85 Mn |
| Mar 31, 2025 | 28.18 Mn |
| Dec 31, 2024 | 33.28 Mn |
| Sep 30, 2024 | 27.07 Mn |
| Jun 30, 2024 | 20.12 Mn |
| Mar 31, 2024 | 25.81 Mn |
| Dec 31, 2023 | 29.07 Mn |
| Sep 30, 2023 | 34.30 Mn |
| Jun 30, 2023 | 39.69 Mn |
| Mar 31, 2023 | 32.22 Mn |
| Dec 31, 2022 | 41.99 Mn |
| Sep 30, 2022 | 66.06 Mn |
| Jun 30, 2022 | 76.04 Mn |
| Mar 31, 2022 | 88.89 Mn |
| Dec 31, 2021 | 103.23 Mn |
| Sep 30, 2021 | 117.65 Mn |